Biotech Values

[gdollasign]

Complete common sense speaking but wouldnt that lend to plain old bad planning in trial design?...3 times?? The only true marker that gets a drug of this type approved i.e. AMRN is to show an actual CV benefit (read fewer incidence). If AMRN cant show it then it will end up the same way as the others mentioned. If it can then we are a mere percentage of future market cap. I dont know if either the ANCHOR or MARINE results highlighted such a benefit. Guess I will have to look.